4.6 Article

TGF-β1-induced CK17 enhances cancer stem cell-like properties rather than EMT in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway

Journal

FEBS JOURNAL
Volume 284, Issue 18, Pages 3000-3017

Publisher

WILEY
DOI: 10.1111/febs.14162

Keywords

cancer stem cell; cervical cancer metastasis; CK17; epithelial-mesenchymal transition; TGF-beta 1

Funding

  1. National Natural Science Foundation of China [81672589, 81072132, 81372781, 81001153, 81572546]
  2. Natural Science Foundation of Shanghai [15ZR1433300]
  3. Shanghai Rising-Star Program [11QA1405200]
  4. Science and Technology Program of Shenzhen [JCYJ20160429161218745]

Ask authors/readers for more resources

Tumor metastasis remains a major obstacle for improving overall cancer survival in cervical cancer (CC), which may be due to the existence of tumor microenvironment-related cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT). The mechanism underlying these processes needs to be further elucidated. Here, we report that TGF-beta 1, one of the key microenvironmental stimuli, can enhance CSC characteristics, facilitate the EMT, and induce CK17. Silencing CK17 expression attenuated CSC-like properties without affecting the EMT markers induced by TGF-beta 1, whereas forced overexpression of CK17 promoted lymphatic metastasis in vivo even without EMT inducement. Inhibitors of ERK1/2 signaling drastically decreased the induction of CK17 mediated by TGF-beta 1. By combined computational and experimental approaches, we identified and validated that MZF1 was a key transcription factor binding to the promoter of CK17. Taken together, these results demonstrate that CK17 induced by the TGF-beta 1-ERK1/2-MZF1 signaling pathway facilitates metastasis by promoting the acquisition of CSC properties rather than by inducing the EMT process in CC, suggesting that this CK17-related signaling pathway might be a suitable target for the development of therapy for CC metastasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available